|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/04/16 Revance Therapeutics, Inc. 10-K 12/31/15 99:11M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.44M
4: EX-10.27 Material Contract HTML 34K
5: EX-10.28 Material Contract HTML 29K
6: EX-10.31 Material Contract HTML 76K
7: EX-10.34 Material Contract HTML 57K
2: EX-10.6 Material Contract HTML 74K
3: EX-10.8 Material Contract HTML 80K
8: EX-21.1 Subsidiaries List HTML 26K
9: EX-23.1 Consent of Experts or Counsel HTML 28K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 33K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 31K
13: EX-32.2 Certification -- §906 - SOA'02 HTML 31K
20: R1 Document and Entity Information HTML 56K
21: R2 Consolidated Balance Sheets HTML 104K
22: R3 Consolidated Balance Sheets (Parenthetical) HTML 55K
23: R4 Consolidated Statements of Operations and HTML 95K
Comprehensive Loss
24: R5 Consolidated Statements of Changes in Convertible HTML 207K
Preferred Stock and of Stockholders? Equity
(Deficit)
25: R6 Consolidated Statements of Changes in Convertible HTML 37K
Preferred Stock and of Stockholders? Equity
(Deficit) (Parenthetical)
26: R7 Consolidated Statements of Cash Flows HTML 194K
27: R8 The Company and Basis of Presentation HTML 47K
28: R9 Summary of Significant Accounting Policies HTML 81K
29: R10 Revenue and License Agreements HTML 36K
30: R11 Medicis Settlement HTML 42K
31: R12 Cash Equivalents and Investments HTML 96K
32: R13 Fair Value Measurements HTML 96K
33: R14 Balance Sheet Components HTML 71K
34: R15 Notes Payable HTML 50K
35: R16 Convertible Notes, Warrants, and Related HTML 44K
Derivatives
36: R17 Interest Expense HTML 61K
37: R18 Commitments and Contingencies HTML 49K
38: R19 Common Stock HTML 46K
39: R20 Convertible Preferred Stock HTML 31K
40: R21 Warrants HTML 37K
41: R22 Net Income (Loss) per Share Attributable to Common HTML 81K
Stockholders
42: R23 Stock Option Plan HTML 288K
43: R24 Income Taxes HTML 94K
44: R25 Defined Contribution Plan HTML 32K
45: R26 Subsequent Events HTML 32K
46: R27 Quarterly Results of Operations (Unaudited) HTML 85K
47: R28 Summary of Significant Accounting Policies HTML 145K
(Policies)
48: R29 Cash Equivalents and Investments (Tables) HTML 94K
49: R30 Fair Value Measurements (Tables) HTML 89K
50: R31 Balance Sheet Components (Tables) HTML 71K
51: R32 Notes Payable (Tables) HTML 33K
52: R33 Interest Expense (Tables) HTML 59K
53: R34 Commitments and Contingencies (Tables) HTML 36K
54: R35 Common Stock (Tables) HTML 44K
55: R36 Net Income (Loss) per Share Attributable to Common HTML 82K
Stockholders (Tables)
56: R37 Stock Option Plan (Tables) HTML 263K
57: R38 Income Taxes (Tables) HTML 83K
58: R39 Quarterly Results of Operations (Unaudited) HTML 84K
(Tables)
59: R40 The Company and Basis of Presentation - Additional HTML 93K
Information (Detail)
60: R41 Summary of Significant Accounting Policies HTML 53K
(Details)
61: R42 Revenue and License Agreements (Details) HTML 53K
62: R43 Medicis Settlement - Additional Information HTML 69K
(Detail)
63: R44 Cash Equivalents and Investments (Details) HTML 51K
64: R45 Cash Equivalents and Investments Remaining HTML 36K
Contractual Maturities Available-for-Sale
Securities (Details)
65: R46 Fair Value Measurements - Schedule of Fair Value HTML 60K
of Financial Instruments (Detail)
66: R47 Fair Value Measurements - Summary of Changes in HTML 35K
Fair Value of Financial Instruments (Detail)
67: R48 Fair Value Measurements (Narrative) (Details) HTML 30K
68: R49 Balance Sheet Components - Additional Information HTML 35K
(Detail)
69: R50 Balance Sheet Components - Schedule of Property HTML 48K
and Equipment, Net (Detail)
70: R51 Balance Sheet Components - Schedule of Prepaid HTML 39K
Expenses and Other Current Assets (Detail)
71: R52 Balance Sheet Components - Schedule of Accruals HTML 48K
and Other Current Liabilities (Detail)
72: R53 Notes Payable - Hercules Notes Payable (Detail) HTML 62K
73: R54 Notes Payable - Essex Capital Notes (Detail) HTML 81K
74: R55 Notes Payable - Summary of Aggregate Total Future HTML 35K
Minimum Lease Payments under the Financing
Obligation (Detail)
75: R56 Convertible Notes, Warrants, and Related HTML 112K
Derivatives - Additional Information (Detail)
76: R57 Interest Expense - Summary of Interest Expense by HTML 49K
Cash and Non-Cash Components (Detail)
77: R58 Commitments and Contingencies - Additional HTML 49K
Information (Detail)
78: R59 Commitments and Contingencies - Schedule of Future HTML 45K
Minimum Lease Payments under Non-Cancelable
Operating Leases (Detail)
79: R60 Common Stock - Additional Information (Detail) HTML 50K
80: R61 Convertible Preferred Stock - Additional HTML 37K
Information (Detail)
81: R62 Warrants - Additional Information (Detail) HTML 98K
82: R63 Net Income (Loss) per Share Attributable to Common HTML 80K
Stockholders - Schedule of Computation of Basic
and Diluted Net Income (Loss) Per Share
Attributable to Common Stockholders (Detail)
83: R64 Net Income (Loss) per Share Attributable to Common HTML 45K
Stockholders - Summary of Common Stock Equivalents
Excluded from Computation of Diluted Net Income
(Loss) Per Share (Detail)
84: R65 Stock Option Plan - Additional Information HTML 127K
(Detail)
85: R66 Stock Option Plan - Summary of Stock Option and HTML 146K
Restricted Stock Award Activity (Details)
86: R67 Stock Option Plan - Stock Options Outstanding and HTML 78K
Exercisable (Details)
87: R68 Stock Option Plan - Summary of Restricted Stock HTML 58K
Award Activity (Details)
88: R69 Stock Option Plan - Fair Value Assumptions HTML 48K
(Details)
89: R70 Stock Option Plan - Schedule of Stock-based HTML 37K
Compensation Expense (Details)
90: R71 Income Taxes - Additional Information (Detail) HTML 61K
91: R72 Income Taxes - Deferred Tax Assets and Liabilities HTML 54K
(Details)
92: R73 Income Taxes - Effective Tax Rate Reconciliation HTML 50K
(Details)
93: R74 Income Taxes - Unrecognized Tax Benefits (Details) HTML 38K
94: R75 Defined Contribution Plan - Additional Information HTML 29K
(Details)
95: R76 Subsequent Events - Additional Information HTML 51K
(Details)
96: R77 Quarterly Results of Operations (Unaudited) - HTML 52K
Additional Information (Details)
98: XML IDEA XML File -- Filing Summary XML 169K
97: EXCEL IDEA Workbook of Financial Reports XLSX 112K
14: EX-101.INS XBRL Instance -- rvnc-20151231 XML 3.05M
16: EX-101.CAL XBRL Calculations -- rvnc-20151231_cal XML 259K
17: EX-101.DEF XBRL Definitions -- rvnc-20151231_def XML 757K
18: EX-101.LAB XBRL Labels -- rvnc-20151231_lab XML 2.19M
19: EX-101.PRE XBRL Presentations -- rvnc-20151231_pre XML 1.23M
15: EX-101.SCH XBRL Schema -- rvnc-20151231 XSD 225K
99: ZIP XBRL Zipped Folder -- 0001479290-16-000031-xbrl Zip 302K
 | Download this zipped .zip folder |
| Files: | rvnc-20151231.xml rvnc-20151231.xsd rvnc-20151231_cal.xml rvnc-20151231_def.xml rvnc-20151231_lab.xml rvnc-20151231_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/23 Revance Therapeutics, Inc. 10-K 12/31/22 109:14M 2/28/22 Revance Therapeutics, Inc. 10-K 12/31/21 106:12M 2/25/21 Revance Therapeutics, Inc. 10-K 12/31/20 109:12M 1/29/21 Revance Therapeutics, Inc. S-8 1/29/21 3:137K 11/09/20 Revance Therapeutics, Inc. 10-Q 9/30/20 83:8.3M |